Kamat - Figure 25
BCG plus Interferon α-2B
References
[23]
Joudi FN, O’Donnell MA; National BCG-Interferon Phase 2 Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24:344–8 https://doi.org/10.1016/j.urolonc.2005.11.026
[24]
Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology. 2008;71:297−301 http://dx.doi.org/10.1016/j.urology.2007.09.050
